Categories: News

Inogen Announces Participation in the 40th Annual J.P. Morgan Healthcare Conference

GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the 40th Annual J.P. Morgan Healthcare Conference.

Inogen’s President and CEO, Nabil Shabshab, is scheduled to present on Wednesday, January 12th, 2022 at 10:30 a.m. PT. Interested parties can access the live audio webcast from the News / Events section of the Investor Relations page on the Inogen website at www.inogen.com. A webcast replay will be available approximately one hour after the conclusion of the live presentation and will remain available for 90 days.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. Inogen primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Contacts

Investor and Media Contacts
Bryan Locke, Mike DeGraff, Gabriella Coffey

Inogen-SVC@sardverb.com
(312) 895-4700

Staff

Recent Posts

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

3 hours ago

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

3 hours ago

Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting

Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a…

3 hours ago

Changing Healthcare Trajectories With Positive Experiences

DaVita works with others in under-resourced communities to offer individualized health engagements, break down mistrust…

3 hours ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its…

3 hours ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Contract Research Organization for the REGAL trial has informed the Company that 72 events have…

3 hours ago